Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

BMS-986242

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BMS, Bayer

Drug class:

Immunomodulator, IDO1 inhibitor

Related drugs:

‹

thymalfasin (0)

chlorogenic acid (0)

dendritic cell activation therapy (0)

minocycline (0)

hydroxychloroquine (7)

quaratusugene ozeplasmid (3)

SQZ-AAC-HPV (1)

HLA-matched donor mononuclear enriched leukocytes (0)

rimiducid activated rivogenlecleucel (0)

GB221 (trastuzumab biosimilar) (0)

GSK2302024A (0)

MVA-BN-HER2 (0)

84AA-API 14AA (0)

nelipepimut-S (0)

engineered donor allograft cell therapy (0)

parvovirus H-1 (0)

FT1050+FT4145 programmed mPB (0)

allodepleted T-cell immunotherapeutics (0)

TAEK-VAC-HerBy vaccine (0)

Undisclosed CISH inactivated TIL (0)

alpha-tocopheroloxyacetic acid (0)

thymalfasin (0)

chlorogenic acid (0)

dendritic cell activation therapy (0)

minocycline (0)

›

almost4years

Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1. (PubMed, ACS Med Chem Lett)

Given the substantial interest around this target for cancer immunotherapy, we sought to identify a structurally differentiated clinical candidate that performs comparably to linrodostat (BMS-986205) in terms of both in vitro potency and in vivo pharmacodynamic effect in a mouse xenograft model. On the basis of its preclinical profile, BMS-986242 was selected as a candidate for clinical development.

almost 4 years ago

Preclinical • Journal

|

IDO1 (Indoleamine 2,3-dioxygenase 1)

|

linrodostat (BMS-986205) • BMS-986242